Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
Not yet recruiting · NCT07549061 · Registry updated 2026-04-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2026-04-29 | NCT07549061 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Chest Hospital | 116 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| 241 West Huaihai Road, Xuhui District, Shanghai, 200030, China. | Shanghai | China | 1 |